Gilead Sciences, Inc. (NASDAQ:GILD) Shares Sold by Foundation Resource Management Inc.

Foundation Resource Management Inc. cut its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 47.1% during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 109,916 shares of the biopharmaceutical company’s stock after selling 97,803 shares during the period. Gilead Sciences accounts for approximately 1.9% of Foundation Resource Management Inc.’s investment portfolio, making the stock its 17th biggest holding. Foundation Resource Management Inc.’s holdings in Gilead Sciences were worth $12,316,000 at the end of the most recent quarter.

Other large investors have also made changes to their positions in the company. Annis Gardner Whiting Capital Advisors LLC increased its position in shares of Gilead Sciences by 158.8% in the 4th quarter. Annis Gardner Whiting Capital Advisors LLC now owns 352 shares of the biopharmaceutical company’s stock valued at $33,000 after acquiring an additional 216 shares during the period. Newbridge Financial Services Group Inc. acquired a new position in shares of Gilead Sciences in the 4th quarter valued at $33,000. Morton Brown Family Wealth LLC acquired a new position in shares of Gilead Sciences in the 4th quarter valued at $35,000. Whipplewood Advisors LLC acquired a new position in shares of Gilead Sciences in the 4th quarter valued at $35,000. Finally, Synergy Investment Management LLC acquired a new position in shares of Gilead Sciences in the 4th quarter valued at $40,000. 83.67% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of equities analysts have weighed in on GILD shares. The Goldman Sachs Group lifted their price objective on Gilead Sciences from $85.00 to $96.00 and gave the company a “neutral” rating in a research note on Wednesday, February 12th. Wells Fargo & Company upped their target price on Gilead Sciences from $120.00 to $140.00 and gave the stock an “overweight” rating in a research note on Wednesday, March 5th. Bank of America upped their target price on Gilead Sciences from $116.00 to $126.00 and gave the stock a “buy” rating in a research note on Wednesday, March 5th. Royal Bank of Canada upped their target price on Gilead Sciences from $84.00 to $90.00 and gave the stock a “sector perform” rating in a research note on Wednesday, February 12th. Finally, Needham & Company LLC restated a “hold” rating on shares of Gilead Sciences in a research note on Wednesday, May 21st. Nine research analysts have rated the stock with a hold rating, fifteen have assigned a buy rating and three have issued a strong buy rating to the company’s stock. According to MarketBeat, Gilead Sciences presently has a consensus rating of “Moderate Buy” and an average target price of $110.55.

Insiders Place Their Bets

In other Gilead Sciences news, CFO Andrew D. Dickinson sold 2,500 shares of Gilead Sciences stock in a transaction dated Thursday, May 15th. The stock was sold at an average price of $99.82, for a total transaction of $249,550.00. Following the completion of the sale, the chief financial officer now directly owns 165,674 shares of the company’s stock, valued at $16,537,578.68. The trade was a 1.49% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, CEO Daniel Patrick O’day sold 10,000 shares of the business’s stock in a transaction dated Friday, May 30th. The shares were sold at an average price of $110.42, for a total value of $1,104,200.00. Following the completion of the sale, the chief executive officer now directly owns 620,268 shares of the company’s stock, valued at $68,489,992.56. The trade was a 1.59% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 43,000 shares of company stock valued at $4,630,310 in the last ninety days. Insiders own 0.27% of the company’s stock.

Gilead Sciences Price Performance

GILD stock opened at $112.46 on Monday. The business has a fifty day moving average of $105.39 and a two-hundred day moving average of $101.64. The company has a quick ratio of 1.20, a current ratio of 1.50 and a debt-to-equity ratio of 1.24. The stock has a market cap of $139.89 billion, a price-to-earnings ratio of 303.95, a price-to-earnings-growth ratio of 0.71 and a beta of 0.29. Gilead Sciences, Inc. has a 52-week low of $62.69 and a 52-week high of $119.96.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings data on Thursday, April 24th. The biopharmaceutical company reported $1.81 earnings per share for the quarter, beating analysts’ consensus estimates of $1.77 by $0.04. The business had revenue of $6.67 billion during the quarter, compared to analysts’ expectations of $6.77 billion. Gilead Sciences had a return on equity of 31.63% and a net margin of 1.67%. The company’s revenue was down .3% on a year-over-year basis. During the same period in the previous year, the firm posted ($1.32) earnings per share. As a group, research analysts anticipate that Gilead Sciences, Inc. will post 7.95 earnings per share for the current year.

Gilead Sciences Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, June 27th. Shareholders of record on Friday, June 13th will be issued a dividend of $0.79 per share. This represents a $3.16 dividend on an annualized basis and a yield of 2.81%. The ex-dividend date of this dividend is Friday, June 13th. Gilead Sciences’s dividend payout ratio (DPR) is 66.53%.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.